<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033627</url>
  </required_header>
  <id_info>
    <org_study_id>TCD Haplo</org_study_id>
    <nct_id>NCT04033627</nct_id>
  </id_info>
  <brief_title>TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia</brief_title>
  <official_title>A Multi-center Prospective Clinical Study in China Using CliniMACS TCRα/β+ and CD45RA+ T Cell Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Stem Cell Transplantation in Children With Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Children's Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell&#xD;
      depleted stem cell grafts from haploidentical donors for hematopoietic stem cell&#xD;
      transplantation in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study will the CliniMACS TCRα/β and CD45RA Systems to deplete TCRα/β+ and&#xD;
      CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donors to&#xD;
      treat pediatric patients who were suffuring form relapsed or refactory leukemia.&#xD;
&#xD;
      Aming to evaluate the safety/tolerability and feasibility of haploidentical PBSC grafts&#xD;
      depleted of TCRα/β+ and CD45RA+ cells using the CliniMACS TCRαβ/CD45RA System in pediatric&#xD;
      patients with hematological malignancies diseases. And the incidence of grade II-IV acute&#xD;
      graft-versus-host disease (GVHD) until Day 100 post-transplantation of this new In Vitro T&#xD;
      cell depletion technology in China.&#xD;
&#xD;
      The investigators will monitor the incidence of grade I acute GVHD until Day 100&#xD;
      post-transplantation, incidence and severity of chronic GVHD after 1 year and 2 years,&#xD;
      incidence of NRM at all visits throughout the study, and graft failure from Day 0 to Day 28&#xD;
      at the same time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log number of In Vitro T cells depletion</measure>
    <time_frame>One week</time_frame>
    <description>Log number of In Vitro T cells depletion using CliniMACS TCRab/CD45RA system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade II-IV acute GVHD</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Incidence of grade II-IV acute graft-versus-host disease (GVHD) until Day 100 post-transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade I aGVHD</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Incidence of grade I acute GVHD until Day 100 post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cGVHD</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence and severity of chronic GVHD in 1 year and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRM</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of NRM at all visits throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft failure</measure>
    <time_frame>1 month</time_frame>
    <description>incidence of Graft failure from Day 0 to Day 28</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapsed Pediatric ALL</condition>
  <condition>Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)</condition>
  <condition>Relapsed Pediatric AML</condition>
  <arm_group>
    <arm_group_label>In Vitro T cell depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In Vitro T cells depletion using CliniMCAS system</intervention_name>
    <description>Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.</description>
    <arm_group_label>In Vitro T cell depletion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pediatric patients with hematological malignancies in complete remission (CR), partial&#xD;
        remission (PR) or with stable disease&#xD;
&#xD;
          -  Acute myeloid leukemia (AML):&#xD;
&#xD;
        Patients with high-risk AML in CR1 Patients with relapsed or primary therapy-refractory AML&#xD;
&#xD;
          -  Acute lymphoid leukemia (ALL):&#xD;
&#xD;
        Patients with high-risk ALL in CR1 Patients with relapsed or primary refractory ALL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years or &lt;8 weeks&#xD;
&#xD;
          -  Patients with progressive disease prior HCT&#xD;
&#xD;
          -  &lt;3 months after preceding hematopoietic cell transplantation (HCT)&#xD;
&#xD;
          -  History of neurological impairment (active seizures, severe peripheral neuropathy,&#xD;
             signs of leukencephalopathy, active CNS infection)&#xD;
&#xD;
          -  Fungal infections with radiological and clinical progression&#xD;
&#xD;
          -  Liver function abnormalities with bilirubin &gt;2 mg/dL and elevation of transaminases&#xD;
             higher than 400 U/L&#xD;
&#xD;
          -  Chronic active viral hepatitis&#xD;
&#xD;
          -  Ejection fraction &lt;40% or shortening fraction &lt;25% on echocardiography&#xD;
&#xD;
          -  Patients with &gt; grade II hypertension by Common Toxicity Criteria (CTC)&#xD;
&#xD;
          -  Creatinine clearance below threshold defined for stem cell transplantation according&#xD;
             to local clinical standard&#xD;
&#xD;
          -  Respiratory failure necessitating supplemental oxygen&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes,&#xD;
             congestive heart failure, myocardial infarction within 6 months prior to the study,&#xD;
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled&#xD;
             infection) which by assessment of the treating physician could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  Patients with a history of psychiatric illness or a condition which could interfere&#xD;
             with their ability to understand the requirements of the study (this includes&#xD;
             alcoholism/drug addiction)&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol or unable to give informed&#xD;
             consent&#xD;
&#xD;
          -  Treatment with any investigational product within 4 weeks prior to study treatment&#xD;
             (transfusion of the IMP)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>luo chengjuan</last_name>
    <phone>+86 021 38626161</phone>
    <phone_ext>82030</phone_ext>
    <email>luochengjuan@scmc.com.cn</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In Vitro T cell depletion</keyword>
  <keyword>haploidentical transplantation</keyword>
  <keyword>GVHD</keyword>
  <keyword>leukemia</keyword>
  <keyword>TCRab</keyword>
  <keyword>CD45RA</keyword>
  <keyword>CliniMACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

